Back to Search
Start Over
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
- Source :
- Lancet. Haematology, 3(8), e379-e387. Lancet Publishing Group, Lancet Haematology, 3(8), E379-E387. ELSEVIER SCI LTD
- Publication Year :
- 2016
-
Abstract
- Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with warfarin in a subgroup of patients with cancer enrolled in the Hokusai-VTE trial. We did a prespecified subgroup analysis in August, 2013, and a post-hoc analysis of non-inferiority and safety in March, 2016, of the patients with cancer enrolled in the randomised, double-blind, double-dummy, multicentre, Hokusai-VTE trial done between Jan 28, 2010, and Oct 31, 2012. In this study, patients aged at least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban 60 mg once per day (or 30 mg once per day for patients with a creatinine clearance of 30-50 mL/min, bodyweight
- Subjects :
- Male
FACTOR XA INHIBITOR
Pyridines
030204 cardiovascular system & hematology
SECONDARY PREVENTION
PROPHYLAXIS
law.invention
chemistry.chemical_compound
0302 clinical medicine
Randomized controlled trial
PRACTICE GUIDELINE UPDATE
law
Edoxaban
Neoplasms
030212 general & internal medicine
AMERICAN SOCIETY
Clotting factor
DABIGATRAN
Hematology
MOLECULAR-WEIGHT HEPARIN
Venous Thromboembolism
Middle Aged
Prognosis
Thrombosis
Pulmonary embolism
Survival Rate
ACTIVE CANCER
Female
medicine.drug
medicine.medical_specialty
Equivalence Trials as Topic
WARFARIN
Dabigatran
03 medical and health sciences
Double-Blind Method
Internal medicine
medicine
Humans
Survival rate
Aged
business.industry
Warfarin
medicine.disease
Surgery
Thiazoles
chemistry
ATRIAL-FIBRILLATION
business
Factor Xa Inhibitors
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 3
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Lancet. Haematology
- Accession number :
- edsair.doi.dedup.....a13b811e5e9bc528c0a9e4643a8e664f